HER2-Targeted Therapies Summit

Paid

Expanding the Clinical Utility of HER2 as a Multi-Tumor Target, Overcoming Resistance Mechanisms & Optimizing Pharmacology of Next Generation Anti-HER2 Drugs The momentum in anti-HER2 drug development is impossible to ignore: Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics, trial design and

14-16 June 2022

Healthcare

13th Annual World ADC London

Paid

The 13th Annual World ADC London returns in 2023 as Europe’s longest standing and definitive antibody-drug conjugate event - and it’s back bigger and better than before! With the recent approval of Astrazeneca and Daiichi Sankyo’s DESTINY-Breast04, supporting Enhertu's use in HER2-low breast cancer as a new therapeutically targetable category, the

13-16 March 2023

Healthcare